<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02585869</url>
  </required_header>
  <id_info>
    <org_study_id>1027-004</org_study_id>
    <nct_id>NCT02585869</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Gemcabene in Patients With Low HDL‐C and Either Normal or Elevated Triglycerides</brief_title>
  <official_title>A 12‐Week, Double‐Blind, Placebo‐Controlled, Randomized, Multicenter Study to Determine the Efficacy and Safety of CI‐1027 in Patients With Low HDL‐C and Either Normal or Elevated Triglycerides</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gemphire Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gemphire Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of gemcabene on HDL‐C, LDL‐C, TG, and
      other lipid levels in patients with low HDL‐C
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 1999</start_date>
  <completion_date type="Actual">June 2001</completion_date>
  <primary_completion_date type="Actual">June 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HDL‐C ‐ percent change from baseline</measure>
    <time_frame>84 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma lipids (eg, LDL‐C, VLDL‐C, TG)- percent change from baseline</measure>
    <time_frame>84 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>84 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory - hematology, chemistry, urinalysis</measure>
    <time_frame>84 days</time_frame>
    <description>Clinical Laboratory Abnormalities</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Gemcabene 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcabene 150 mg once daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcabene 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcabene 300 mg once daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcabene 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcabene 600 mg once daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcabene 900 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcabene 900 mg once daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily (QD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcabene 150 mg</intervention_name>
    <description>Blinded capsules and tablets, 150 mg, once daily, 84 days</description>
    <arm_group_label>Gemcabene 150 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcabene 300 mg</intervention_name>
    <description>Blinded capsules and tablets, 300 mg, once daily, 84 days</description>
    <arm_group_label>Gemcabene 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcabene 600 mg</intervention_name>
    <description>Blinded capsules and tablets, 600 mg, once daily, 84 days</description>
    <arm_group_label>Gemcabene 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcabene 900 mg</intervention_name>
    <description>Blinded capsules and tablets, 900 mg, once daily, 84 days</description>
    <arm_group_label>Gemcabene 900 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Blinded capsule and tablets, once daily, 84 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or naturally postmenopausal or surgically menopausal women

          -  18 to 80 years of age

          -  Baseline HDL‐C &lt;35 mg/dL (0.9 mmol/L)

        Exclusion Criteria:

          -  Creatine phosphokinase (CPK) &gt;3 × the upper limit of normal (ULN)

          -  Body Mass Index (BMI) &gt;35 kg/m2

          -  Uncontrolled Hypertension &gt;95 mm Hg

          -  Uncontrolled diabetes mellitus (HbA1c &gt;10%)

          -  Renal dysfunction (blood urea nitrogen [BUN] or creatinine &gt;2 × ULN);

          -  Hepatic dysfunction (aspartate aminotransferase [AST] or alanine aminotransferase
             [ALT] &gt;2 × ULN)

          -  Uncontrolled hypothyroidism (TSH &gt;1.5 × ULN)

          -  Myocardial infarction, severe or unstable angina pectoris, coronary angioplasty,
             coronary artery bypass graft, or any other major cardiovascular event resulting in
             hospitalization in previous 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Bays HE, McKenney JM, Dujovne CA, Schrott HG, Zema MJ, Nyberg J, MacDougall DE; Gemcabene Study Group. Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol. Am J Cardiol. 2003 Sep 1;92(5):538-43.</citation>
    <PMID>12943873</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2015</study_first_submitted>
  <study_first_submitted_qc>October 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2015</study_first_posted>
  <last_update_submitted>October 22, 2015</last_update_submitted>
  <last_update_submitted_qc>October 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lipid Regulator</keyword>
  <keyword>TG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

